Eli Lilly and Company (NYSE:LLY) Shares Sold by Citizens Business Bank

Citizens Business Bank lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 12.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 954 shares of the company’s stock after selling 139 shares during the period. Citizens Business Bank’s holdings in Eli Lilly and Company were worth $742,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Koss Olinger Consulting LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at $5,154,000. Mayfair Advisory Group LLC boosted its stake in Eli Lilly and Company by 5.7% in the 1st quarter. Mayfair Advisory Group LLC now owns 1,489 shares of the company’s stock worth $1,158,000 after buying an additional 80 shares during the last quarter. Financial Partners Group LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $232,000. ADE LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $201,000. Finally, Optas LLC increased its stake in Eli Lilly and Company by 2.2% during the first quarter. Optas LLC now owns 2,501 shares of the company’s stock worth $1,946,000 after acquiring an additional 53 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Jefferies Financial Group raised their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $812.72.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,441 shares of the firm’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $915.02, for a total value of $1,318,543.82. Following the completion of the sale, the insider now directly owns 97,367,369 shares in the company, valued at $89,093,089,982.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $915.02, for a total value of $1,318,543.82. Following the transaction, the insider now directly owns 97,367,369 shares in the company, valued at approximately $89,093,089,982.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold 791,145 shares of company stock worth $673,704,508 in the last quarter. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 1.0 %

LLY opened at $914.37 on Tuesday. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $916.83. The company has a fifty day moving average of $814.40 and a 200-day moving average of $740.86. The stock has a market cap of $869.03 billion, a PE ratio of 134.66, a price-to-earnings-growth ratio of 1.97 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the business earned $1.62 EPS. The firm’s revenue was up 26.0% compared to the same quarter last year. On average, sell-side analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.